Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study
Fecha
2021Language
en
Materia
Resumen
Background: Chronic obstructive pulmonary disease (COPD) is a multifactorial clinical condition, characterized by chronic progressive (or worsening) respiratory symptoms, structural pulmonary abnormalities, and impaired lung function, and is often accompanied by multiple, clinically significant comorbid disorders. In 2017, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a new report on COPD prevention, diagnosis and management, aiming at personalizing the maintenance therapeutic approach of the stable disease, based on the patients’ symptoms and history of exacerbations (ABCD assessment approach). Our objective was to evaluate the implementation of GOLD suggestions in everyday clinical practice in Greece. Methods: This was a cross-sectional observational study. Sixty-five different variables (demographics, vital sign measurements, COPD-related medical history parameters, comorbidities, vaccination data, COPD severity based on spirometry measurements, COPD stage based on the ABCD assessment approach, COPD treatments) were collected from 3615 nation-wide COPD patients (Greece). Results: The mean age at the time of initial COPD diagnosis was 63.8 (± 10.2). Almost 60% of the subjects were classified into group B, while the remaining patients were falling into groups A (18%) and D (21%), and only a small minority of patients belonged to Group C, according to the ABCD assessment approach. The compliance of respiratory physicians to the GOLD 2017 therapeutic suggestions is problematic, especially when it comes to COPD patients belonging to Group A. Conclusion: Our data provide valuable information regarding the demographic and medical profile of COPD patients in Greece, the domains which the revised ABCD assessment approach may show some clinical significance on, and the necessity for medical practitioners dealing with COPD patients to adhere closer to international recommendations for the proper management of the disease. © 2021, The Author(s).
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: A multicenter, case-control study
Panopoulos S., Thomas K., Georgiopoulos G., Boumpas D., Katsiari C., Bertsias G., Drosos A.A., Boki K., Dimitroulas T., Garyfallos A., Papagoras C., Katsimbri P., Tziortziotis A., Adamichou C., Kaltsonoudis E., Argyriou E., Vosvotekas G., Sfikakis P.P., Vassilopoulos D., Tektonidou M.G. (2021)Objectives: Evidence on comorbidity prevalence in antiphospholipid syndrome (APS) and its difference from high comorbidity burden rheumatic diseases is limited. Herein, we compare multiple comorbidities between APS and RA. ... -
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
Christodoulou C., Kalogera-Fountzila A., Karavasilis V., Kouvatseas G., Papandreou C.N., Samantas E., Varaki K., Papadopoulos G., Bobos M., Rallis G., Razis E., Goudopoulou A., Kalogeras K.T., Syrigos K.N., Fountzilas G. (2017)Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing ... -
Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: Results from the BIOSIGNAL study
Arnold M., Schweizer J., Nakas C.T., Schütz V., Westphal L.P., Inauen C., Pokorny T., Luft A., Leichtle A., Arnold M., Bicvic A., Fischer U., De Marchis G.M., Bonati L.H., Müller M.D., Kahles T., Nedeltchev K., Cereda C.W., Kägi G., Bustamante A., Montaner J., Ntaios G., Foerch C., Spanaus K., Von Eckardstein A., Katan M. (2021)Aims: Lipoprotein(a) [Lp(a)] is a recognized causal risk factor for atherosclerotic cardiovascular disease but its role for acute ischaemic stroke (AIS) is controversial. In this study, we evaluated the association of Lp(a) ...